# Binimetinib Plus Encorafenib Real Life Investigation of Next Generation Melanoma Treatment

> **NCT04045691** · — · RECRUITING · sponsor: **Pierre Fabre Pharma GmbH** · enrollment: 750 (estimated)

## Conditions studied

- Melanoma Stage IV
- Melanoma Stage III

## Interventions

- **DRUG:** Encorafenib
- **DRUG:** Binimetinib

## Key facts

- **NCT ID:** NCT04045691
- **Lead sponsor:** Pierre Fabre Pharma GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2019-10-17
- **Primary completion:** 2026-12
- **Final completion:** 2027-09
- **Target enrollment:** 750 (ESTIMATED)
- **Last updated:** 2021-01-19

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04045691

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04045691, "Binimetinib Plus Encorafenib Real Life Investigation of Next Generation Melanoma Treatment". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04045691. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*